ArticleTheranostics2018
Systematic Assessment of Strategies for Lung-targeted Delivery of MicroRNA Mimics.
Article in Theranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 22 citations in OpenAlex.
- Modulation of experimental acute lung injury by exosomal miR-7704 from mesenchymal stromal cells acts through M2 macrophage polarization.Molecular therapy. Nucleic acids · 2024Article
- Biomarker-based approach to determine etiology and severity of pulmonary hypertension: Focus on microRNA.Frontiers in cardiovascular medicine · 2022Review
- miR-124-3p Delivered Using Exosomes Attenuates the Keratinocyte Response to IL-17A Stimulation in Psoriasis.Oxidative medicine and cellular longevity · 2022Article
- Inhibition of microRNA-30a alleviates vascular remodeling in pulmonary arterial hypertension.Molecular therapy. Nucleic acids · 2021Article
- Adverse immunological responses against non-viral nanoparticle (NP) delivery systems in the lung.Journal of immunotoxicology · 2021Review
- Review
- A rapid and reliable CE-LIF method for the quantitative analysis of miRNA-497 in plasma and organs and its application to a pharmacokinetic and biodistribution study.RSC advances · 2020Article
- MicroRNA Nanotherapeutics for Lung Targeting. Insights into Pulmonary Hypertension.International journal of molecular sciences · 2020Review
- MicroRNA 27a Is a Key Modulator of Cholesterol Biosynthesis.Molecular and cellular biology · 2020Article
- Target prediction and validation of microRNAs expressed from FSHR and aromatase genes in human ovarian granulosa cells.Scientific reports · 2020Article
- MiR-1539 and Its Potential Role as a Novel Biomarker for Colorectal Cancer.Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
There is considerable interest in the use of synthetic miRNA mimics (or inhibitors) as potential therapeutic agents in pulmonary vascular disease; however, the optimal delivery method to achieve high efficiency, selective lung targeting has not been determined. Here, we sought to investigate the relative merits of different lung-targeted strategies for delivering miRNA mimics in rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.